Mounjaro for Heart Failure: Off-Label Risks, Benefits, and What the Evidence Actually Shows

What Mounjaro Is and What It Is Not Approved For

Tirzepatide, marketed as Mounjaro by Eli Lilly, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. The FDA granted approval in May 2022 specifically for improving glycemic control in adults with type 2 diabetes. A higher-dose formulation (Zepbound) received separate approval for chronic weight management in November 2023.

Neither approval covers heart failure of any type. That distinction matters. When a physician prescribes Mounjaro to treat heart failure, they are doing so off-label. Off-label prescribing is legal and common in medicine (estimates suggest roughly 20% of all prescriptions are off-label), but it shifts the evidence burden. The prescriber is relying on clinical judgment and emerging data rather than the full regulatory dossier the FDA requires for an approved indication.

For patients, the practical consequence is straightforward: insurers rarely cover off-label use without a prior authorization fight, and even then approval is not guaranteed. The retail cost of Mounjaro exceeds $1,000 per month. That financial barrier shapes who can realistically access this therapy for heart failure and who cannot.

Why Heart Failure Specialists Are Interested in Tirzepatide

Heart failure with preserved ejection fraction accounts for roughly half of all heart failure cases, and obesity is both a risk factor and a driver of disease progression. Excess adiposity increases blood volume, promotes systemic inflammation, and stiffens the left ventricle. For years, no drug meaningfully addressed the obesity-HFpEF phenotype. Standard therapies like SGLT2 inhibitors (empagliflozin, dapagliflozin) help, but weight-neutral mechanisms leave the adiposity component untouched.

GLP-1 receptor agonists changed the calculus. The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in patients with overweight or obesity and established atherosclerotic cardiovascular disease. That trial did not specifically enroll patients with heart failure as the primary condition, but it primed the cardiology community to ask a sharper question: could incretin-based therapies treat the hemodynamic and structural consequences of obesity-related HFpEF directly?

Tirzepatide's dual GIP/GLP-1 mechanism produces greater weight loss than GLP-1 agonists alone. In the SURMOUNT-1 trial (N=2,539), tirzepatide 15 mg produced 22.5% mean weight loss at 72 weeks in adults with obesity without diabetes. That magnitude of weight reduction has downstream effects on cardiac filling pressures, left atrial size, and exercise capacity. The hypothesis was mechanistically sound. It needed a dedicated trial.

The SUMMIT Trial: What It Found

SUMMIT (Study of Tirzepatide on the Progression and Regression of Heart Failure with Preserved Ejection Fraction) was a randomized, double-blind, placebo-controlled Phase 3 trial enrolling 731 adults with HFpEF (ejection fraction ≥50%) and a BMI ≥30 kg/m². Participants received tirzepatide (titrated to a maximum of 15 mg weekly) or placebo for 52 weeks [1].

The primary endpoint was a composite of cardiovascular death or a worsening heart failure event (hospitalization or urgent visit for heart failure). Results were significant.

Tirzepatide reduced the composite endpoint by 38% compared with placebo (hazard ratio 0.62 to 95% CI 0.41 to 0.95, P=0.026). Worsening heart failure events drove most of the benefit. Cardiovascular deaths were numerically lower but the trial was not powered to detect a mortality difference [1].

Secondary outcomes reinforced the primary finding. Participants on tirzepatide walked an average of 18.3 meters farther on the 6-minute walk test than those on placebo. The Kansas City Cardiomyopathy Questionnaire clinical summary score (a validated patient-reported measure of heart failure symptoms and physical limitation) improved by 4.5 points more in the tirzepatide group. Mean body weight fell by 11.6% with tirzepatide versus 0.8% with placebo [1].

"These findings indicate that tirzepatide may offer clinically meaningful benefits for patients with HFpEF and obesity, a population with limited treatment options," stated Dr. Milton Packer, one of the trial investigators, in the NEJM publication [1].

Putting SUMMIT in Context: Strength and Limits of the Evidence

A single positive Phase 3 trial with 731 participants is meaningful. It is not definitive. The trial was adequately powered for its primary composite endpoint, and the 38% reduction exceeded what many cardiologists expected. But several limitations require honest accounting.

First, the patient population was specific: BMI ≥30, ejection fraction ≥50%, and functional class II-IV. Patients with HFrEF (reduced ejection fraction) were excluded. The findings cannot be generalized to all heart failure patients. Second, the 52-week follow-up does not answer whether the benefit persists at two, three, or five years. Third, the trial enrolled predominantly White participants (approximately 80%), and racial and ethnic diversity was limited [1].

Using the GRADE framework, the current evidence for tirzepatide in HFpEF with obesity sits at moderate certainty. There is one well-conducted RCT showing a clinically meaningful effect on a hard composite endpoint, but it is a single trial, modest in size, with short follow-up. Replication is needed. The American Heart Association's 2024 scientific sessions highlighted the SUMMIT results prominently but stopped short of issuing a formal recommendation pending additional data [2].

For context, the STEP-HFpEF trial (N=529) showed that semaglutide 2.4 mg improved symptoms and exercise capacity in HFpEF patients with obesity, with a 7.8-point improvement in KCCQ-CSS versus placebo at 52 weeks [3]. The SUMMIT trial's KCCQ-CSS improvement of 4.5 points was smaller, but SUMMIT used a harder primary endpoint (CV death or HF events) rather than symptom scores alone, making direct comparison between the two trials imprecise.

Safety Profile: Gastrointestinal and Cardiac Considerations

The most common adverse events in SUMMIT were gastrointestinal: nausea (24.0% vs 4.9% placebo), diarrhea (16.4% vs 7.4%), and vomiting (10.0% vs 2.2%). These rates are consistent with the known GI side-effect profile of incretin therapies and generally decreased after the dose-titration phase [1].

Serious adverse events occurred in 15.9% of tirzepatide-treated patients versus 22.2% on placebo. That difference was driven largely by fewer heart failure hospitalizations in the tirzepatide group. There were no clear signals for pancreatitis, thyroid carcinoma, or gallbladder events, though the trial was too small and too short to exclude rare risks [1].

One concern specific to heart failure patients is the potential for volume depletion. Tirzepatide slows gastric emptying and reduces food intake, which can compound diuretic-induced dehydration. Patients on loop diuretics (furosemide, bumetanide, torsemide) may need dose adjustments during the titration phase. The Endocrine Society's 2023 clinical practice guideline on pharmacologic treatment of obesity notes that GLP-1 receptor agonists require monitoring for dehydration in patients on concurrent diuretics [4].

Heart rate increases of 2-4 beats per minute have been observed across tirzepatide trials. For most patients, this is clinically inconsequential. For patients with tachycardia-mediated cardiomyopathy or atrial fibrillation with rapid ventricular response, the effect warrants monitoring [5].

"We titrate slowly and watch volume status closely," noted Dr. Gregg Fonarow, chief of the UCLA Division of Cardiology, in a commentary on incretin therapies in heart failure. "The GI side effects can mimic decompensation symptoms, and clinicians need to distinguish nausea from drug effect versus nausea from worsening heart failure" [6].

The Off-Label Prescribing Decision: A Clinical Framework

Prescribing tirzepatide off-label for heart failure is not a binary yes-or-no question. It is a risk-benefit calculation that depends on the individual patient. Several factors tilt the balance.

Patients most likely to benefit include those with confirmed HFpEF (ejection fraction ≥50%), a BMI ≥30 kg/m², and persistent symptoms (NYHA class II-III) despite guideline-directed medical therapy including SGLT2 inhibitors. These patients closely match the SUMMIT enrollment criteria, and the evidence applies most directly to them [1].

Patients where caution is warranted include those with HFrEF (no trial data), BMI <30 (no trial data), advanced kidney disease (eGFR <25 mL/min/1.73m², excluded from SUMMIT), a history of pancreatitis, or personal/family history of medullary thyroid carcinoma or MEN2 syndrome. The FDA prescribing information for Mounjaro carries a boxed warning regarding thyroid C-cell tumor risk based on rodent studies [7].

Patients where the decision is premature include those with NYHA class I symptoms (minimal limitation), those who have not yet optimized standard HFpEF therapies (SGLT2 inhibitors, mineralocorticoid receptor antagonists, diuretics), or those without confirmed obesity as a contributing factor to their heart failure phenotype.

The cost barrier cannot be ignored. At over $1,000 per month out of pocket, off-label tirzepatide is inaccessible for many patients. Some clinicians have used manufacturer savings programs or appealed to insurers with supporting literature, but success is inconsistent. The American College of Cardiology acknowledged cost as a systemic barrier to translating SUMMIT findings into practice [8].

How Tirzepatide Compares to Other Heart Failure Therapies

Standard HFpEF management has evolved considerably in recent years. SGLT2 inhibitors are the closest pharmacologic parallel. The EMPEROR-Preserved trial (N=5,988) showed empagliflozin reduced the composite of cardiovascular death or heart failure hospitalization by 21% in HFpEF patients (HR 0.79 to 95% CI 0.69-0.90), with benefits observed regardless of diabetes status [9]. The DELIVER trial (N=6,263) showed dapagliflozin achieved a similar 18% reduction [10].

Tirzepatide's 38% relative risk reduction in SUMMIT is numerically larger, but the comparison is imperfect. SUMMIT enrolled only patients with obesity, while EMPEROR-Preserved and DELIVER included patients across the BMI spectrum. SUMMIT was smaller and shorter. SGLT2 inhibitors have a broader evidence base, FDA approval for heart failure, established safety profiles over longer follow-up, and generic availability (empagliflozin patent considerations notwithstanding).

The practical question for clinicians is whether to add tirzepatide on top of an SGLT2 inhibitor in obese HFpEF patients who remain symptomatic. In SUMMIT, approximately 37% of participants were on SGLT2 inhibitors at baseline, and subgroup analyses suggested the benefit of tirzepatide was consistent regardless of SGLT2 inhibitor use, though confidence intervals were wide [1].

Sacubitril/valsartan (Entresto), FDA-approved for HFrEF and studied in the PARAGON-HF trial for HFpEF, showed a non-significant 13% reduction in the primary endpoint in HFpEF (HR 0.87 to 95% CI 0.75 to 1.01, P=0.06) [11]. The FDA subsequently broadened Entresto's indication to include certain HFpEF patients, but the evidence is weaker than for SGLT2 inhibitors or, now, tirzepatide in the obese subgroup.

What Ongoing Trials Will Tell Us

Eli Lilly has initiated additional studies to evaluate tirzepatide in broader heart failure populations. Confirmatory trials are expected to expand enrollment criteria beyond BMI ≥30 and may include patients with HFmrEF (mildly reduced ejection fraction, 41-49%). An outcomes trial with longer follow-up (2-3 years) would address the durability question and provide mortality data that SUMMIT could not [8].

The National Institutes of Health ClinicalTrials.gov registry lists several investigator-initiated studies examining tirzepatide's effects on cardiac structure and function using advanced imaging endpoints (cardiac MRI, echocardiographic strain). These mechanistic studies will help clarify whether tirzepatide's benefit comes primarily from weight loss and volume reduction or from direct myocardial effects [12].

Until confirmatory data emerge, professional societies are unlikely to issue strong recommendations. The current stance from the Heart Failure Society of America and ACC positions tirzepatide as a promising option warranting further study rather than a standard-of-care therapy for HFpEF [2].

Practical Guidance for Patients Considering Off-Label Tirzepatide

If you have heart failure and are considering asking your physician about tirzepatide, several steps can make that conversation more productive.

Confirm your heart failure subtype. Tirzepatide data exist for HFpEF with obesity. If your ejection fraction is below 50% or your BMI is below 30, the current evidence does not apply to you. Ask your cardiologist for your most recent echocardiogram numbers.

Verify that standard therapies are optimized. SGLT2 inhibitors, diuretics, blood pressure management, and cardiac rehabilitation should all be addressed before adding an off-label incretin agent. Stacking therapies before optimizing proven ones adds cost and complexity without clear benefit.

Discuss the cost openly. Ask whether your insurance plan has any pathway for off-label coverage, whether the manufacturer's savings card applies, and what the realistic out-of-pocket expense would be. A therapy that works but cannot be sustained for 12 or more months may produce transient benefit followed by rebound weight gain and symptom recurrence [13].

Report GI symptoms accurately. Nausea and reduced appetite from tirzepatide can overlap with symptoms of worsening heart failure. Your care team needs to differentiate between drug side effects and disease progression. Keep a symptom log during the titration phase, particularly during the first 8 to 12 weeks.

Expect slow titration. The standard tirzepatide protocol starts at 2.5 mg weekly and increases by 2.5 mg every 4 weeks. In heart failure patients, some clinicians extend the interval to 6-8 weeks per step to minimize volume shifts and GI disruption.

The starting dose in SUMMIT was 2.5 mg weekly, matching the approved diabetes titration schedule, with a target of 15 mg weekly by week 20 [1].